World's Best Scientists 2026 revealed!

D-Index & Metrics

Neuroscience

D-Index
69
Citations
25490
World Ranking
2583
National Ranking
1220

Best Publications

  • Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.

    Christopher G. Goetz;Barbara C. Tilley;Stephanie R. Shaftman;Glenn T. Stebbins

  • Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan.

    Christopher G. Goetz;Stanley Fahn;Pablo Martinez-Martin;Werner Poewe

  • Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial

    R. Holloway;I. Shoulson;K. Kieburtz;M. McDermott

  • AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial

    Peter A LeWitt;Ali R Rezai;Maureen A Leehey;Steven G Ojemann

  • Levodopa in the treatment of Parkinson's disease: current controversies.

    C. Warren Olanow;Yves Agid;Yoshi Mizuno;Alberto Albanese

  • Transferrin and Iron in Normal, Alzheimer's Disease, and Parkinson's Disease Brain Regions

    D. A. Loeffler;J. R. Connor;P. L. Juneau;B. S. Snyder

  • Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005)

    Peter A. LeWitt;Peter A. LeWitt;M. Guttman;James W. Tetrud;Paul J. Tuite

  • A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains.

    James R. Connor;Brian S. Snyder;Paolo Arosio;David A. Loeffler

  • Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics.

    Peter A. LeWitt

  • Levodopa for the Treatment of Parkinson's Disease

    Peter A. LeWitt

  • Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.

    Ira Shoulson;David Oakes;Stanley Fahn;Anthony Lang

  • Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study

    Peter A. LeWitt;Kelly E. Lyons;Rajesh Pahwa

  • The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

    R S Burns;P A LeWitt;M H Ebert;H Pakkenberg

  • A Randomized, Double-blind, Placebo-Controlled Trial of Subcutaneously Injected Apomorphine for Parkinsonian Off-State Events

    Richard B. Dewey;J. Thomas Hutton;Peter A. LeWitt;Stewart A. Factor

  • Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment.

    Mark Stacy;Annette Bowron;Mark Guttman;Robert Hauser

  • Norepinephrine deficiency in Parkinson's disease: The case for noradrenergic enhancement

    Alberto J. Espay;Peter A. LeWitt;Horacio Kaufmann

  • Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders.

    D.A. Loeffler;P.A. LeWitt;P.L. Juneau;A.A.F. Sima

  • Cognitive impairments in Parkinson's disease: Distinguishing between effort-demanding and automatic cognitive processes

    Herbert Weingartner;Stanley Burns;Rita Diebel;Peter A. LeWitt

  • Reliability of a new scale for essential tremor

    Rodger Elble;Cynthia Comella;Stanley Fahn;Mark Hallett

  • TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial.

    C Warren Olanow;Anthony H V Schapira;Peter A LeWitt;Karl Kieburtz

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Recently Published Articles